Scilex Posts $115M Q2 Loss, Cash Dwindles to $0.6M, Going Concern Doubt Reiterated
SCLX has more than doubled off its 52-week low of $2.615 on light trading volume (0.2× avg).
Summary
Scilex Holding Co. reported a $115.0 million Q2 2026 net loss, cash of just $0.6 million, and reiterated substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · SCLX
-
Q2 Net Loss More Than Doubles
Net loss of $115.0 million for Q2 2026, up from $44.0 million in Q2 2025, driven by $82.4 million in unrealized losses on the Datavault equity investment and a $28.8 million loss on the compound derivative of the terminated St. James loan.
-
Cash Nearly Depleted
Cash and cash equivalents fell to $0.6 million as of June 30, 2026, down from $5.0 million at December 31, 2025. Negative working capital widened to $476.0 million.
-
Going Concern Doubt Reiterated
Management reiterated substantial doubt about the company's ability to continue as a going concern for one year after the financial statement issuance date.
-
St. James Loan Terminated
The Scilex-St. James Loan Agreement was terminated on March 16, 2026, resulting in a $28.8 million charge and the write-off of $66.3 million in collateral shares.
Analysis · SCLX · Life Sciences
A net loss of $115.0 million for Q2 2026—more than double the $44.0 million loss a year earlier—underscores the severity of Scilex Holding Co.'s financial distress. Cash and cash equivalents fell to $0.6 million from $5.0 million at year-end, while negative working capital widened to $476.0 million. Management reiterated substantial doubt about the company's ability to continue as a going concern. The quarter included $82.4 million in unrealized losses on its Datavault equity investment and a $28.8 million loss on the compound derivative tied to the terminated St. James loan. The company also disclosed a $12 million Vivasor stock repurchase agreement and a $100 million term sheet with iHolding Group, but neither has closed. With cash nearly depleted and debt maturities looming, the company's survival depends on completing these financing transactions.
At the time of this filing, SCLX was trading at $6.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $57.4M. The 52-week trading range was $2.62 to $21.34. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.